This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
On this episode of Cheddar Innovates: Sidechef CEO breaks down how it's building a platform to make recipe shopping easy; Luum CEO explains the process of having a robot put on eyelash extensions; A look at Curiosity Stream's new original series, 'Evolve.'
Moderna launched a clinical trial of a COVID-19 booster shot specifically targeting the omicron variant. The first participant has already received a dose, and Moderna expects to enroll about 600 adults total, split between two groups. In the first group, participants will have previously received two doses of the Moderna vaccine, and in the second, participants will have received its booster. Dr. Paul Burton, chief medical officer at Moderna, joined Cheddar’s Opening Bell to discuss the trial, yearly boosters, and what lies ahead for the company.
With the 2022 Beijing Winter Olympics right around the corner, experts are warning that climate change is threatening not only the event but also the future of snow sports. Despite being the world's top polluter, China is hoping to use the event to demonstrate the country's commitment to fighting climate change, and pledging to host a "low carbon" games. Xubin Zeng, professor of hydrology and atmospheric sciences at the University of Arizona, joins Cheddar News.
New research is suggesting that giving extra cash to low-income mothers can actually influence the brain development of their infants. These findings provide the first rigorous evidence of how payments and monetary support can affect children in the early years of life. Authors of the study, Nathan Fox, professor in the department of human development at the University of Maryland, and Sonya Troller-Renfree, postdoctoral research associate at Teachers College at Columbia University, join Cheddar News to discuss.
Communities of color are disproportionately affected by climate change and continuously feel the impacts. Mark Magaña, founding president and CEO of Green Latinos joined All Hands to discuss.
Neil Young has come up with an ultimatum for Spotify: his music or Joe Rogan’s podcast. This comes over concerns that the podcast is spreading COVID-19 vaccine misinformation to its listeners. "The Joe Rogan Experience," which is exclusive to Spotify, is currently the number one streamed podcast on the platform.
Commercial and residential buildings account for 13% of carbon emissions in the U.S., according to the EPA, and one company says it has a solution. Runwise says it has updated the boiler and heating systems of thousands of buildings, and that its technology not only lowers carbon output but also saves landlords money. Lee Hoffman, Co-Founder and COO of Runwise, joined Cheddar Climate to discuss.
Jo Ruxton, Founder of Ocean Generation, joins Cheddar Climate, where she explains the threat that plastic pollution poses to marine life, but elaborates on why we shouldn't be looking to ban plastic entirely. Ruxton also discusses her biggest takeaways while producing the film ‘A Plastic Ocean.'
President Joe Biden's Build Back Better deal seems all but finished after months of Democratic infighting and the Senate's deadlock over certain provisions. But Biden mentioned during a press conference marking his first year in office that 'chunks' of the bill could be passed. Is that enough motivation to force Democrats to rally around certain parts of the bill - especially those that focus on climate and green energy? Andrew Freedman, Energy and Climate Reporter at Axios, joins Cheddar Climate to discuss whether Senate Democrats will be able to rally around climate provisions, if the idea of passing Build Back Better in 'chunks' is doable, and more.
